vTv to propose path forward for AD candidate despite Phase III miss

vTv Therapeutics Inc. (NASDAQ:VTVT) said azeliragon (TTP488) missed the co-primary endpoints compared with placebo in Part B of the Phase III STEADFAST trials to treat mild Alzheimer’s disease. Despite the

Read the full 304 word article

User Sign In